NetScientific PLC Director Dealings (1835P)
30 Setembro 2013 - 3:03AM
UK Regulatory
TIDMNSCI
RNS Number : 1835P
NetScientific PLC
30 September 2013
30 September 2013
NetScientific plc
("NetScientific" or the "Group")
Director Dealings
NetScientific, the healthcare medical technology company,
announces that on 27 September 2013 it received notification that,
on 27 September 2013, Barry Wilson, Non Executive Director of the
Group, purchased 6,150 ordinary shares of 5p each in the capital of
the Group ("Ordinary Shares") at a price of 161p per share.
Following this transaction, Barry Wilson will hold 15,525
Ordinary Shares representing approximately 0.04% of the issued
ordinary share capital of the Group.
- Ends -
For further information, please contact:
NetScientific plc Tel: +44 (0) 20 3590 8877
Farad Azima, Chief Executive Officer
Liberum Capital (Nomad & Broker) Tel: +44 (0) 20 3100 2000
Chris Bowman / Christopher Britton
/ Thomas Bective
Bell Pottinger Tel: +44 (0) 20 7861 3232
Daniel de Belder
Company website:www.netscientific.net
About NetScientific
NetScientific is a healthcare medical technology company that
identifies, develops and commercialises research and technologies
originating from leading universities, teaching hospitals and
research institutes globally, particularly in the United Kingdom
and the United States. The Group is primarily focused on
identifying and developing research and technologies for use in
five chronic disease areas within the healthcare diagnostics
sector: (i) cardiovascular; (ii) liver; (iii) cancer; (iv)
metabolic; and (v) digital health.
The Group's core strategy is to fund and develop translational
technologies that offer transformative benefits to peoples' lives
and society through improved diagnosis, monitoring and treatment of
chronic disease. Chronic diseases account for more than 70 per
cent. of healthcare expenses in each of the United States and the
United Kingdom, according to the Centers for Disease Control and
Prevention and the UK Department of Health. Accordingly, reducing
the cost of diagnosing, monitoring and treating chronic disease has
become one of the key challenges to the global healthcare sector.
Consequently, the Directors believe the Group's five areas of focus
represent highly attractive growth markets with significant unmet
medical need for technological development, and in which the
Group's management has a significant amount of experience,
expertise and strong existing networks. The Directors also believe
that focusing on these areas will provide the Group with a
competitive advantage over private equity funds and generalised IP
commercialisation companies, enabling it to create value for
shareholders.
The Group's current Portfolio contains five standalone
subsidiaries, two of which are close to key value inflection points
and are currently the primary focus of the Group:
-- WANDA, Inc., which is developing a virtual patient engagement
system that aims to improve the effectiveness of remote monitoring
of chronic disease patients; and
-- Vortex BioSciences, Inc., which is developing a blood-based
cancer test that detects circulating tumour cells.
Within the Group's Portfolio there are also ten pipeline
opportunities currently undergoing evaluation and development.
Business Model
The Group aims to identify promising research projects and
technologies that have the potential to be translated from research
laboratory to clinical and commercial application.
The Group provides researchers and technologists with funding
and funding support, technical guidance and commercial expertise in
return for rights over their project IP. The Group aims to develop
each project and IP through the proof of concept stage and onward
to full commercialisation. As part of the process, the most
attractive opportunities are formed into portfolio companies, in
which the Group typically takes a majority equity interest in
return for further funding and guidance.
The Group aims to grow the equity value of its interests in its
portfolio companies through various key value inflection points
such as clinical trials, regulatory approvals, collaborative
funding arrangements, first revenues and follow-on growth. In turn,
these value inflection points create exit or out-licensing
opportunities for the Group through trade sales, licensing
arrangements with larger market participants or IPOs.
The Group has active collaborations with a number of US and UK
institutions worldwide and has established dialogues with several
other institutions that may lead to future pipeline projects.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSLIFLAADIAFIV
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024